Biological
COVID-19 Vaccine MVC-COV1901 clinical trials
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2020
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 11
Who runs them
Industry 9 · Other 2
Medigen Vaccine Biologics Corp. (9) · Chang Gung Memorial Hospital (1) · Taoyuan General Hospital (1)
Often tested with
Tested in the same studies.
ChAdOx1 nCoV-19 (1) · BNT162 Vaccine (1) · 2019-nCoV Vaccine mRNA-1273 (1)
Studies
Open first, then newest update. How each study uses COVID-19 Vaccine MVC-COV1901 is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and AboveCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05198596Written as MVC-COV1901
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222CompletedPhase 3Medigen Vaccine Biologics Corp.NCT05426343Written as MVC-COV1901
- A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in AdultsCompletedPhase 3Medigen Vaccine Biologics Corp.NCT05011526Written as MVC-COV1901
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension StudyCompletedPhase 2Medigen Vaccine Biologics Corp.NCT05048849Written as MVC-COV1901(S protein with adjuvant)
- The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 VaccineStatus unknownPhase 1/2Chang Gung Memorial HospitalNCT05132855Written as MVC-COV1901
- A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly AdultsCompletedPhase 2Medigen Vaccine Biologics Corp.NCT04822025Written as MVC-COV1901 (High-Dose)
- A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-studyCompletedPhase 2Medigen Vaccine Biologics Corp.NCT05038618Written as MVC-COV1901(S protein with adjuvant)
- A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in AdolescentsCompletedPhase 2Medigen Vaccine Biologics Corp.NCT04951388Written as MVC-COV1901(S protein with adjuvant)
- A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19CompletedPhase 1Medigen Vaccine Biologics Corp.NCT04487210Written as MVC-COV1901
- A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in AdultCompletedPhase 2Medigen Vaccine Biologics Corp.NCT04695652Written as MVC-COV1901(S protein with adjuvant)
- A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19Status unknownPhase 4Taoyuan General HospitalNCT05097053Written as MVC-COV1901(3 Months)